Abstract: Ischemic events can culminate in acute myocardial infarction with irreversible cardiac lesions that cannot be restored due to the limited regenerative capacity of the heart. Tissue engineering proposes therapeutic alternatives by using biomaterials to resemble the native extracellular medium combined with healthy and functional cells. This research focused on developing a natural thermosensitive hydrogel, its physical-chemical characterization and in vitro biocompatibility determination. Hydrogels’ morphological characterization was carried out through scanning electron microscopy and its chemical characterization by employing Infrared Spectroscopy technic. In addition, the biocompatibility was determined using fetal human ventricular cardiomyocytes cell line RL-14 and the MTT cytotoxicity test according to the ISO 10993-5 standard. Four biocompatible and thermosensitive hydrogels were obtained with a three-dimensional internal structure and two gelation times. The results show the potential of the hydrogel to increase the cell survival rate to the cardiac cell therapies under investigation and lay the foundations to continue with its characterization and biological evaluation both in vitro and in vivo models.
Abstract: Endothelial Progenitor Cell (EPC) based therapies continue to be of interest to treat ischemic events based on their proven role to promote blood vessel formation and thus tissue re-vascularisation. Current strategies for the production of clinical-grade EPCs requires the in vitro isolation of EPCs from peripheral blood followed by cell expansion to provide sufficient quantities EPCs for cell therapy. This study aims to examine the use of different biomolecules to significantly improve the current strategy of EPC capture and expansion on collagen type I (Col I). In this study, four different biomolecules were immobilised on a surface and then investigated for their capacity to support EPC capture and proliferation. First, a cell microarray platform was fabricated by coating a glass surface with epoxy functional allyl glycidyl ether plasma polymer (AGEpp) to mediate biomolecule binding. The four candidate biomolecules tested were Col I, collagen type II (Col II), collagen type IV (Col IV) and vascular endothelial growth factor A (VEGF-A), which were arrayed on the epoxy-functionalised surface using a non-contact printer. The surrounding area between the printed biomolecules was passivated with polyethylene glycol-bisamine (A-PEG) to prevent non-specific cell attachment. EPCs were seeded onto the microarray platform and cell numbers quantified after 1 h (to determine capture) and 72 h (to determine proliferation). All of the extracellular matrix (ECM) biomolecules printed demonstrated an ability to capture EPCs within 1 h of cell seeding with Col II exhibiting the highest level of attachment when compared to the other biomolecules. Interestingly, Col IV exhibited the highest increase in EPC expansion after 72 h when compared to Col I, Col II and VEGF-A. These results provide information for significant improvement in the capture and expansion of human EPC for further application.
Abstract: Numerous investigations suggest that Mesenchymal
Stem Cells (MSCs) in general represent a valuable tool for therapy of
symptoms related to chronic inflammatory diseases. Blue Horizon
Stem Cell Therapy Program is a leading provider of adult and
children’s stem cell therapies. Uniquely we have safely and
efficiently treated more than 600 patients with documenting each
procedure. The purpose of our study is primarily to monitor the
immune response in order to validate the safety of intravenous
infusion of human umbilical cord blood derived MSCs (UC-MSCs),
and secondly, to evaluate effects on biomarkers associated with
chronic inflammation. Nine patients were treated for conditions
associated with chronic inflammation and for the purpose of antiaging.
They have been given one intravenous infusion of UCMSCs.
Our study of blood test markers of 9 patients with chronic
inflammation before and within three months after MSCs treatment
demonstrates that there is no significant changes and MSCs treatment
was safe for the patients. Analysis of different indicators of chronic
inflammation and aging included in initial, 24-hours, two weeks and
three months protocols showed that stem cell treatment was safe for
the patients; there were no adverse reactions. Moreover data from
follow up protocols demonstrates significant improvement in energy
level, hair, nails growth and skin conditions. Intravenously
administered UC-MSCs were safe and effective in the improvement
of symptoms related to chronic inflammation. Further close
monitoring and inclusion of more patients are necessary to fully
characterize the advantages of UC-MSCs application in treatment of
symptoms related to chronic inflammation.
Abstract: Cell processing techniques for gene and cell therapies use several separate procedures for gene transfer and cell separation or elimination, because no current technology can offer simultaneous multi-functional processing of specific cell sub-sets in heterogeneous cell systems. Using our novel on-demand nonstationary intracellular events instead of permanent materials, plasmonic nanobubbles, generated with a short laser pulse only in target cells, we achieved simultaneous multifunctional cell-specific processing with the rate up to 50 million cells per minute.